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Abstract: Numerous studies have revealed the pleiotropic functions of tumor necrosis factor 
alpha (TNF-α), and have linked it with several neurodegenerative disorders. This review 
describes the signaling pathways induced by TNF-α via its two receptors (TNFR1 and 
TNFR2), and their functions in neurodegenerative processes as in Alzheimer’s disease (AD), 
Parkinson’s disease (PD), multiple sclerosis (MS), and ischemic stroke. It has become clear 
that TNF-α may exert divergent actions in neurodegenerative disorders, including 
neurodegenerative and neuroprotective effects, which appear to depend on its signaling via 
either TNFR1 or TNFR2. Specific targeting of these receptors is a promising therapeutic 
strategy for many disorders. 
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1. Introduction 
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine implicated in multiple 
inflammatory diseases, including cancer, rheumatoid arthritis, and in neurodegeneration as in 
Alzheimer’s disease (AD), stroke, multiple sclerosis (MS), and Parkinson’s disease (PD) [1–5]. TNF-α 
is synthesized as a type II transmembrane protein of 26 kDa and forms a stable homo-trimeric molecule 
(mTNF-α) to exert its pleiotropic biological activities. It can be processed by proteolytic cleavage via 
TNF-α converting enzyme (TACE/ADAM17) to a 17 kDa monomeric protein, which is biologically 
active as a soluble homo-trimeric molecule of 51 kDa (sTNF-α). TNF-α induces various cellular 
responses through its interaction with two distinct transmembrane receptors, the 55 kDa TNF receptor 
type I (TNFR1) and the 75 kDa TNF receptor type II (TNFR2). Under normal physiological conditions, 
TNFR1 is ubiquitously expressed in various cell types and tissues, whereas TNFR2 is predominantly 
expressed at low levels in immune cells and endothelial cells [6–9]. TNFR1 activation can be induced 
by either sTNF-α or mTNF-α, and TNFR2 activation is predominantly initiated by mTNF-α [10]. TNF-α 
is classically known to exert pro-apoptotic functions via TNFR1 [11] and via TNFR2 in co-operation 
with TNFR1 [12,13]. On the contrary, more recent evidence clearly indicates that TNF-α induces cell 
survival and cellular proliferation via its TNFR2 [14,15]. This led to new insights that TNF-α exerts 
opposing effects via its two receptors with respect to neurodegeneration and neuroprotection. The potent 
pro-inflammatory functions of TNF-α in the brain play an important role in the etiology of 
neurodegenerative disorders such as ischemia/ischemic stroke, MS, and AD [14,16–18]. Therefore, a 
thorough understanding of TNF-α signaling pathways in neurodegenerative disorders can promote the 
development of effective agents in the treatment of these conditions. 
This review will discuss TNF-α-mediated functions in the healthy and unhealthy central nervous 
system (CNS), focusing on TNF-α-mediated signaling pathways via its receptors, TNFR1 and TNFR2. 
Finally, we will examine these signaling pathways as potential therapeutic strategies for 
neurodegenerative disorders, focusing on AD, PD, ischemic stroke, and MS. 
2. TNF-α Receptor Signaling Pathways 
2.1. TNF-α Receptor 1 Signaling 
The two distinct transmembrane receptors of TNF-α are characterized by a conserved domain of  
N-terminal repeating cysteine-rich motif in extracellular regions that specifically interact with diverse 
TNF-related ligands [19]. The conserved domain is necessary and sufficient for the preassembly of 
TNFR complexes that bind TNF-α trimers and mediate downstream signaling [20]. However, the 
intracellular domains of the two receptors lack homologous sequences [21], suggesting that distinct 
signaling pathways emanate from the two receptors. TNFR1 is distinguished from TNFR2 by its 
intracellular death domains (DDs) [22]. The extracellular domain of TNFR1 contains a well-ordered 
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cysteine-rich amino-terminal, known as the preligand binding assembly domain (PLAD). PLAD favors 
pre-assembly of TNFR1 into trimeric complexes and functions as a preventative measure for receptor 
auto-activation and is essential for ligand binding [23]. TNFR1 can be activated by both sTNF-α and 
mTNF-α [10]. TNFR1-induced apoptosis involves formations of two sequential signal complexes 
(complex I and complex II) that are separated both temporally and spatially, but is limited by the 
successful activation of complex I [24]. After TNF-α binding, the activated TNFR1 acts via its 
intracellular DDs to recruit the core adaptor TNFR-associated death domain (TRADD) [25–27]. 
Furthermore, receptor-interacting protein 1 (RIP1) is recruited rapidly and modified with non-degradative 
poly-ubiquitin chains [28,29]. TRADD subsequently recruits other proteins such as TNFR-associated 
factor 2 (TRAF2) [30], inhibitor of apoptosis protein 1 (cIAP1), and inhibitor of apoptosis protein 2 
(cIAP2) [31], forming the initial signaling complex I. This signaling complex with RIP1 ubiquitination 
initiates the later activation of the catalytic IκB kinase (IKK) complex [32]. The activated IKK complex, 
which consists of an IKKα subunit and an IKKβ subunit, functions as an essential regulatory subunit of 
the IKK complex (IKKγ/NEMO), which subsequently phosphorylates the inhibitor of the kappa-B (IκB) 
complex [33]. The IκB complex is then degraded via the ubiquitin-proteasome. Consequently, NF-κB 
composed of p50/p52 and RelA (p65)/RelB subunits is released and translocated into the nucleus to 
initiate the transcription of anti-apoptotic genes, cIAP-1, cIAP-2, TRAF1, TFAF2 as well as cellular FLICE-
like inhibitory protein (cFLIP), to inhibit caspase 8 release from complex II [30,32,34–36] (Figure 1). The 
caspase-8 inhibitor cFLIP(L), which is harbored in complex II, simultaneously inhibits the release of  
pre-caspase 8 [24,34]. 
When complex I signaling fails to activate the NF-κB pathway in some instances, the activated 
TNFR1 will recruit complex II to trigger apoptotic processing (Figure 1). After ligand binding to TNFR1, 
the silencer of DDs is dissociated from the intracellular domains of TNFR1, and recruits the adaptor 
proteins such as TRADD, RIP1, TRAF2, and Fas-associated death domain (FADD) and pre-caspase 8 
to form complex II [35]. In the activated complex, FADD triggers pre-caspase 8 activation, resulting in 
the release of p18/p12 fragments that can trigger downstream caspase cascades to participate in apoptotic 
processes [24]. This pro-apoptotic signaling mechanism involves FADD and caspase 8 as the key factors 
to trigger apoptosis [36,37]. Upon recruitment of FADD and caspase-8, initiation of apoptosis via 
caspase-8 is mainly determined by levels of the anti-apoptotic protein cFLIP(L) [38]. NF-κB activation 
triggered by complex I signaling determines the availability of the cFLIP(L) protein at the moment 
complex II is formed [38]. Therefore, adequate production of cFLIP(L) via NF-κB upon complex I 
signaling prevents subsequent caspase-8-mediated apoptosis of the complex II signaling pathway [39]. 
TNFR1 signaling can also trigger caspase-independent programmed necrosis (necroptosis) in Jurkat 
cells and in ischemic brain injury [40–42]. It was shown in mouse embryonic TNFR1−/− fibroblast cells 
that necrotic cell death is primarily dependent on TNFR1-mediated pathways [43]. In this process, RIPs, 
FADD, and TRAF2 elements are still the critical components to form complex IIb [43] (Figure 1). RIP1 
is required for the formation of complex IIb [44]. Additionally, RIP3 assembly is essential for RIP1 
recruitment to this complex and is identified as a crucial kinase to phosphorylate RIP1, which in turn 
phosphorylates RIP3 to form the RIP1-RIP3 pre-necrotic complex [45]. This activated complex 
phosphorylates the downstream mixed lineage kinase domain-like protein (MLKL) which subsequently 
triggers necrosis [46]. MLKL is therefore a critical factor in RIP3-mediated downstream necroptotic 
pathways. Dephosphorylation of RIP3 via protein phosphatase 1B (Ppm1b) restricts necroptosis [47]. In 
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addition to caspase suppression, cFLIP proteins can potentially inhibit TNF-induced necroptosis [48]. 
Necroptosis is a newly discovered pathway of cell death with essential functions in tissue homeostasis 
and development, and is particularly studied in cancers and skin diseases. However, research on this 
pathway remains rather limited in CNS conditions. In primary hippocampal neurons, necroptosis was 
induced via RIP3 upon an ischemic insult [49]. Moreover, it was recently shown in vivo in mice that 
intracerebroventricular injection with TNF-α caused RIP3-mediated necroptosis of hippocampal 
neurons [50]. Besides neurons, necroptosis can also occur in activated (by stimulation with different 
inflammatory stimuli, including TNF-α) primary microglia upon the inhibition of caspase-8 [51]. 
Interestingly, in mixed cultures (where also primary neurons and astrocytes were present), necroptosis 
of activated microglia protected neurons from cell death [51]. Yuan’s group [52] reported that 
necroptosis in cortical neurons mainly depends on the RIP1-RIP3-MLKL signaling pathway induced via 
TNF-α/TNFR1 in MS. Przedborski’s group [53], however, showed that necroptosis-driven death of 
motor neurons triggered by amyotrophic lateral sclerosis (ALS) involves the RIP1-MLKL signaling 
pathway independent of TNF signaling. As such, it seems that RIP1-MLKL-mediated neuronal 
necroptosis may be induced in different ways, both dependent or independent of TNF-α. 
 
Figure 1. Multiple forms of TNFR1 signaling activation are mediated through intracellular 
protein complex assembly. The trimeric TNF-α engagement of TNFR1 leads to cellular 
apoptosis or cell survival via the distinct complex signaling pathways. 
  
Antibodies 2015, 4 373 
 
2.2. TNF-α Receptor 2 Signaling 
Compared to TNFR1-mediated pathways, TNFR2-mediated signaling is still less well understood. 
TNFR2 is typically expressed at a low level in cells of the immune system, and is activated primarily by 
mTNF-α [10]. Unlike TNFR1, TNFR2 does not include a death domain (DD). Trimerization of TNFR2 
is induced upon binding of mTNF-α, leading to the recruitment of TRAF2 to the intracellular TRAF 
binding motif, which subsequently causes the recruitments of TRAF1, cIAP1, and cIAP2 [54] (Figure 2). 
TRAF2 is a key mediator in this signaling pathway that triggers the subsequent signaling cascades 
leading to activation of NF-κB [55]. The activation TRAF2-cIAP1/2 complex is recruited to NF-κB-
inducing kinase (NIK) by TRAF3, resulting in proteosomal degradation of NIK [56]. TNFR2 activation 
by mTNF-α maintains NIK stabilization via induction of TRAF3 degradation, and thereby activates 
IκBα, leading to phosphorylation and activation of IKKα. Phosphorylated IKKα consequently activates 
the NF-κB precursor protein p100 [57]. This noncanonical NF-κB activation is independent of IKKβ 
and IKKγ [56]. Moreover, it has been reported that human TNFR2 contains a second intracellular 
binding region for TRAF2 and that this intracellular region can recruit TRAF2, which leads to the 
activation of NF-κB, dependent on activation of NIK and IκBα. Deletion of this binding region impairs 
the ability of TNFR2 to activate NF-κB [58]. 
TNFR2-mediated activation of NF-κB can also occur via the phosphoinositide 3-kinases (PI3K)-
protein kinase B/serine-threonine kinase (PKB/Akt) signaling pathway [59] (Figure 2). The 
phosphorylated IκB is degraded via the ubiquitin-proteasome and NF-κB is translocated into the nucleus 
to initiate transcription [60]. TNFR2-mediated NF-κB activation is downregulated by phosphatase and 
the tensin homolog deleted on chromosome 10 (PTEN), which is a strong inhibitor of the PI3K-PKB/Akt 
pathway. However, NF-κB activation via TNF-α leads to downregulation of PTEN [61]. 
In addition to NF-κB activation, signaling via TNFR2 can elicit various non-apoptotic responses 
including c-Jun N-terminal kinase (JNK) or p38 mitogen-activated protein kinases (MAPK) that depend 
on the recruitment of TRAF2 to the different intracellular binding sites of TNFR2 [54,62]. In these 
signaling pathways, TNFR2 binds TRAF2 to its intracellular region, and subsequently recruits TRAF1, 
TRAF3, cIAP1, and cIAP2 [63,64]. According to spatial and temporal separation, this complex binds to 
a MAPK kinase kinase (MAP3K) protein called MEKK1 and enhances the activity of this kinase and 
the phosphorylation of JNK-activating kinase (JNKK1) [65], and thereby stimulates JNK activation to 
promote downstream signaling pathways which mediate cell survival. It should be noted, however, that 
while acute activation of JNK via TRAF2 has been related to cell survival, prolonged activation may 
also lead to apoptosis [66–68]. TNF-α-mediated JNK activation depends at least in part on MEKK1 [62,65]. 
As opposed to TRAF1 and TRAF3, TRAF2 positively regulates JNK activation [55]. It has been 
suggested that TNFR2 harbors two sequences that are adaptors specific for JNK signaling [69]. TNFR2-
TRAFs/cIAPs can mediate activation of the p38 MAPK signaling pathway. TRAF2 is a major player to 
promote activation of the p38 MAPK signaling pathway [70]. In this pathway, the TRAFs/cIAPs 
complex recruits RIP and subsequently activates MKK3 to initiate p38 MAPK activation [27,71,72]. 
TRAF2, TRAF1, and cIAP play a pivotal role not only in TNFR1 signaling pathways but also in 
TNFR2 pathways. This implicates that there could be a crosstalk between the two receptors [73]. It has 
been demonstrated that the depletion of TRAF2 induced by TNFR2 activation specifically accelerates 
the TNFR1-dependent caspase 8 activation [74–76]. TNFR2 signaling in a certain circumstance may 
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therefore enhance TNFR1-mediated apoptosis by caspase 8 activation. Crosstalk between TNFR1 and 
TNFR2 is complicated and dependent on the physiologic environment and signaling kinetics between 
the two receptors. We have previously described TNFR crosstalk in [73]. 
 
Figure 2. Multiple forms of TNFR2 signaling activation are mediated through intracellular 
protein complex assembly. The transmembrane trimeric TNF-α engagement of TNFR2 leads 
to cellular survival via the distinct complex signaling pathways. PKB/Akt signaling is 
described in [59,73]. 
3. TNF and Its Receptors—Involvement in Neurodegenerative Disorders 
3.1. Alzheimer’s Disease 
AD is a progressive neurodegenerative disorder, and the most common cause of dementia [77]. 
Besides the well-known pathological hallmarks of AD, including the formation of toxic aggregates of 
amyloid beta (Aβ) and hyperphosphorylated tau proteins, neuroinflammation was more recently 
described to play a fundamental role in the pathophysiological processes of AD, in which TNF-α in 
particular could be an important mediator [78] (also see Table 1). Evidence for the involvement of TNF-α 
in AD emanates from various research disciplines. On a genetic level, multiple polymorphisms in the 
TNF-α gene may be associated with the risk of developing AD [79]. For example, the TNF-α G308A 
promoter polymorphism, which may cause higher TNF-α expression levels, has been found to increase 
the risk of AD in certain populations [80–82]. At the protein level, plasma and serum TNF-α protein 
Antibodies 2015, 4 375 
 
levels are elevated in AD [83–85]. Moreover, TNF-α levels in AD brain tissue were found to be 
increased, originating from microglia surrounding Aβ plaques [86–88]. Besides promoting ongoing  
pro-inflammatory processes in the AD brain, increased TNF-α levels can also affect the accumulation of 
Aβ. For example, it has been suggested that higher levels of pro-inflammatory cytokines may interfere 
with phagocytosis of fibrillar Aβ via mechanisms that need further clarification [89]. Yet, in monocyte-
derived macrophages, it was shown that cytokines, including TNF-α, could directly decrease the 
expression of mediators involved in the degradation of aggregated proteins, such as insulin degrading 
enzyme, thereby interfering with the breakdown of fibrillary Aβ [90]. Moreover, TNF-α may increase 
Aβ production by enhancing beta-secretase (BACE1) expression (via NF-κB-dependent pathways) and 
activity and stimulating gamma-secretase activity via JNK-dependent MAPK signaling [91,92]. 
The extents of signaling through TNFR1 and TNFR2 are an important aspect to consider when 
interpreting the role of increased TNF-α in AD. TNFR1 protein levels in human post-mortem AD brain 
tissue are significantly increased as compared to non-demented age-matched controls, while TNFR2 
protein levels are decreased [88,93]. Moreover, it appeared that TNF-α in the AD brain has an increased 
binding affinity to TNFR1 but a decreased affinity for TNFR2 [94]. Interestingly, Zhao et al. also 
reported significantly increased levels of TRADD and caspase-3 in AD brains [88]. Data from these 
studies suggest a shift towards TNFR1-mediated signaling in AD. On a genetic level, a polymorphism 
in exon 6 of the TNFR2 gene is associated with late-onset AD [95]. The functional consequences of this 
polymorphism in TNFR2, however, remain, to our knowledge, unclear. 
Studies using AD mouse models also have aimed to further the understanding of the role of TNF-α 
receptors in AD pathology. Montgomery et al. (2011) found that deletion of both TNFR1 and TNFR2 
in triple-transgenic AD mice (3xTg-AD) significantly exacerbated AD pathology [96]. This suggests 
that total blockage of TNF-α signaling is not beneficial in this condition, and that both TNFRs should 
be appreciated separately. Interestingly, Montgomery et al. (2013) supported this idea by showing that 
the silencing of TNFR2 aggravates TNFR1-mediated Aβ and tau pathology in aged 3xTg-AD mice [97]. 
Moreover, knock-down of either TNFR2 or both TNF-α receptors caused enhanced neuroinflammation [97]. 
Likewise, the group of Shen recently reported that genetic deletion of TNFR2 enhances AD pathology 
in the APP23 mouse model for AD, while TNFR2 overexpression can reverse these findings [98]. The 
same group also showed that genetic deletion of TNFR1 resulted in inhibition of Aβ production in 
APP23 mice, and prevented learning and memory deficits [91]. McAlpine et al. showed that the 
inactivation of TNFR1 signaling diminished Aβ pathology in 3xTgAD mice, and that administration of 
inhibitors of sTNF-α (which predominantly activates TNFR1) had similar beneficial effects in 3xTgAD 
mice [99]. Moreover, intracerebroventricular injection of oligomeric Aβ resulted in cognitive decline in 
wild-type mice, but did not affect cognition in TNFR1 knockout mice [3]. Finally, in an in vitro study 
with the SH-SY5Y neuroblastoma cell line, silencing of TNFR2 aggravated the neurotoxic effect of  
Aβ [100]. These findings overall seem to support the hypothesis that increased TNFR1 signaling and/or 
decreased TNFR2 signaling may play an important role in AD pathology. 
3.2. Parkinson’s Disease 
Neuroinflammation—besides the aggregation of alpha-synuclein (α-synuclein) proteins—also plays 
an important role in PD, by directly or indirectly contributing to the degeneration and death of 
dopaminergic neurons in the substantia nigra [101,102]. The role of TNF-α and its receptors in PD was 
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also previously reviewed by McCoy and Tansey (2008) [103]. TNF-α levels are significantly increased 
in the brain and CSF of PD patients [102,104], and increased TNFR1 levels were found in the substantia 
nigra of PD patients [105]. Evidence for the involvement of TNF-α and its receptors in mechanisms of 
PD progression is described in studies with different PD animal models and in vitro models (also see  
Table 1). For example, some models aim to mimic the α-synucleinopathy that is observed in PD by 
overexpressing wild-type or mutant α-synuclein. In vitro, BV2 cells (a murine microglial cell line) 
showed elevated TNF-α secretion upon α-synuclein overexpression [106], and primary murine microglia 
presented a significant increase in TNF-α expression after exposure to mutant α-synuclein [107]. In vivo, 
overexpression of α-synuclein via recombinant adeno-associated virus (AAV-synuclein) injection into 
the substantia nigra was also found to increase TNF-α expression [108,109]. Another PD model makes 
use of 6-hydroxydopamine (6-OHDA), a toxic dopamine analogue which leads to dopaminergic neuron 
death upon administration. In vitro, it was shown that selective activation of TNFR2 (by TNC-scTNFR2, 
a TNFR2-specific agonist) rescued cultured neurons from 6-OHDA-induced cell death [110]. In vivo, 
peripheral and intranigral injection in rats with specific inhibitors of sTNF-α (XPro-1595 and XENP345, 
respectively) was shown to reduce 6-OHDA-induced death of dopamine neurons [111–114]. 
Considering that sTNF-α preferably binds and activates TNFR1 rather than TNFR2, and that TNFR1 is 
highly expressed by dopamine neurons, it was suggested that the neuroprotective effects of these sTNF-α 
blockers may have resulted mostly from attenuated signaling via TNFR1 [112,115]. These findings 
indicate that TNF-α and its receptors exert similar functions in PD as previously described for AD; TNF-α 
functioning is shifted towards increased TNFR1 signaling, and certain neuroprotective effects induced 
via TNFR2 signaling are decreased. It should be noted, however, that studies using mice with TNFR1 
and/or TNFR2 deletions have led to contradictory findings about their roles in PD pathology, which may 
be due to differences in the PD models used, as reviewed in [103]. For example, it was shown that mice 
lacking both TNFR1 and TNFR2 in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP, a 
dopaminergic neurotoxin) model for PD were completely protected against the dopaminergic 
neurotoxicity of MPTP, while mice lacking either TNFR1 or TNFR2 were not protected [116]. 
3.3. Ischemic Stroke 
Ischemic stroke can arise when a blood vessel supplying blood to the brain is obstructed. Sudden loss 
of blood flow to a brain region causes damage and cell death in the (nutrient- and oxygen-) deprived 
area. Upon ischemic stroke, different brain cell types in proximity of the ischemic lesion site (including 
neurons, microglia, and astrocytes) increase their production of TNF-α. This has been shown in human 
brain tissue as well as in experimental animal models of stroke [117–120]. As reviewed by Pan and 
Kastin (2007), TNF-α was shown to have both detrimental and beneficial effects in stroke [121]. Several 
studies reported that inhibition of TNF-α (e.g., by etanercept, a human TNFR2-IgG Fc fusion protein) 
reduces infarct size and neuroinflammation [122–125], while, on the other hand, complete knockout of 
both TNFRs increases the sensitivity for stroke and aggravates neuronal damage [5]. Moreover, in stroke 
in vitro and animal models, pre-treatment with TNF-α (which models ischemic preconditioning) 
mediates neuroprotective effects after ischemia [126,127]. In accordance with the above-discussed 
disorders, complete abolition of TNF-α signaling, as well as exaggerated TNF-α signaling, are 
detrimental in ischemic stroke. This may likely depend on the contribution of TNF-α/TNFR1 and TNF-α/ 
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TNFR2 signaling (also see Table 1). In addition to TNF-α, its receptors are also upregulated in stroke. In 
a rat model for stroke by permanent middle cerebral artery occlusion (MCAO), TNFR1 upregulation 
was apparent after 6 h, while TNFR2 upregulation followed at 24 h [121,128]. Time differences in 
upregulation of TNFR1 and TNFR2 expression can be explained by studies showing that TNFR1 
expression is mainly regulated by post-translational processes, while TNFR2 is believed to be controlled 
by transcriptional factors such as NF-κB [129–131]. Studies investigating the effects of TNFR1- and 
TNFR2-mediated signaling in ischemia and stroke have resulted in contrasting findings. For example, it 
was shown by Gary et al. (1998) that the infarct size in mice after MCAO is significantly larger in 
TNFR1 knockout mice than in wild-type or TNFR2 knockout mice [132]. Lambertsen et al. similarly 
showed larger infarct sizes in TNFR1 knockout mice compared with wild-type and TNFR2 knockout 
mice in a focal cerebral ischemia model [133]. Moreover, TNFR1 was implicated in ischemic 
preconditioning, in which a short ischemic event may result in resistance to severe ischemic injury [134]. 
It was shown that ischemic preconditioning (induced by a 10 min transient MCAO) caused TNFR1 
upregulation in neurons, and that this upregulation in TNFR1 expression in ischemic preconditioning 
was associated with a smaller infarct size [134]. Taoufik et al. reported that TNFR1 signaling is 
responsible for upregulating different neuroprotective mediators, i.e., vascular endothelial growth factor, 
upon an ischemic lesion in the mouse brain [135,136]. In addition, a study investigating mice deficient of 
TNFR1 and transgenic for human TNFR2 implicated that TNFR2 signaling induced pro-inflammatory 
responses in the CNS vasculature, resulting in inflammatory ischemia [137]. These findings imply a 
neuroprotective role for TNFR1, while TNFR2 signaling may have detrimental effects by aggravating 
neuroinflammatory processes. However, conflicting data is also present. For example, our group 
previously showed that absence of TNFR1 in mice strongly reduced neurodegeneration after retinal 
ischemia-reperfusion, while a lack of TNFR2 exacerbated neurodegeneration [16]. This finding indicates 
that TNFR1 signaling may augment neuronal death and TNFR2 may promote neuroprotection. In 
accordance, an in vitro study with the SH-SY5Y neuroblastoma cell line showed that silencing of TNFR2 
aggravated cell injury upon hypoxic conditions [100]. Moreover, in the immature brain, TNFR1-JNK 
signaling was responsible for neuroinflammation and neurovascular damage in lipopolysaccharide 
(LPS)-sensitized hypoxic-ischemia brain injury [138]. The different models of ischemia that were used 
may, in part, explain these contradictory findings. Furthermore, the duration of the induced ischemia 
(acute/transient vs. chronic) might potentially affect the pathways, kinetics, and outcomes of TNF signaling. 
Also, the acuteness of ischemic lesions may explain differences between ischemic stroke and other 
neurodegenerative disorders like AD and PD, which gradually develop over a longer period of time. In 
disorders that develop slowly, the expression levels and distribution of TNFRs may gradually change 
during the pathological process (e.g., resulting in lower TNFR2 expression in AD brains). This might 
explain how acute insults could result in different effects of TNF-α, as compared to conditions in which 
lesions arise over a longer period of time. 
3.4. Multiple Sclerosis 
MS is a chronic demyelinating disease of the CNS, resulting in disrupted nerve signaling and therefore 
a wide range of neurological symptoms. It has been suggested that the demyelination of axons is due to 
the death of myelin-forming oligodendrocytes, which in part may be caused by detrimental inflammatory 
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and immune responses targeted to these cells [139]. The involvement of TNF-α in MS has been explored 
in several studies [103] (also see Table 1). Increased TNF-α levels were found in MS lesions [140,141]. 
In a transgenic mouse model that overexpresses murine TNF-α specifically in the CNS, it was 
demonstrated that constitutive TNF-α expression leads to spontaneous development of a chronic 
inflammatory demyelinating disorder [142]. In addition, peripherally increased TNF-α levels have been 
associated with synaptic instability in the brain, and as such may contribute to sensory and cognitive 
impairments as seen in MS [143]. On the other hand, complete knockout of TNF-α in experimental 
autoimmune encephalomyelitis (EAE, an MS animal model) mice caused deleterious effects, including 
increased inflammation, demyelination, and higher mortality as compared to control mice [144,145]. In 
the cuprizone model (a toxin causing reversible demyelination), complete knockout of TNF-α in mice 
resulted in delayed demyelination (suggesting that TNF-α promotes acute demyelination) as well as 
delayed remyelination (suggesting that in later stages, TNF-α promotes remyelination) [146]. The 
beneficial versus detrimental effects of TNF-α in MS may greatly depend on its signaling via either 
TNFR1 or TNFR2. Akassoglou et al. (1998) demonstrated a dominant role for TNFR1 signaling in  
TNF-mediated oligodendrocyte apoptosis and primary demyelination [147]. In addition, TNFR1 was 
suggested to contribute to inflammatory infiltration of the EAE spinal cord [148]. Interestingly, it was 
recently shown in different studies that administration of an antagonistic antibody that selectively targets 
TNFR1 ameliorated disease symptoms in the EAE mouse model [18,149]. Also, inhibition of sTNF-α 
by XPro-1595 protected EAE mice from clinical symptoms and improved axon preservation and 
remyelination, indicating a detrimental effect of sTNF-α (which signals mostly via TNFR1) [150,151]. 
Furthermore, studies showed that TNFR1 knockout mice do not develop EAE, or have a less severe 
disease course. TNFR2 knockout mice, on the other hand, were seen to develop more extensive 
demyelination and aggravated EAE disease symptoms [18,152–154]. Similarly, in the cuprizone model, 
TNFR2 was shown to be responsible for TNF-α mediated remyelination and proliferation of 
oligodendrocyte precursor cells [146]. A neuroprotective role of TNFR2 on oligodendrocyte progenitor 
cells was also directly shown in in vitro studies by Maier et al. (2013) [155]. In this study, primary 
oligodendrocytes from transgenic mice expressing human TNFR2 were shown to be protected from 
oxidative stress after preconditioning the cells with a TNFR2 specific agonist. This protective effect 
might be elicited by TNFR2-mediated induction of anti-apoptotic and cell survival genes [155]. Taking 
the above results together, it may not be a surprise that general blockage of TNF-α signaling can have a 
net detrimental effect, by also inhibiting the neuroprotective signaling of TNF-α. This idea is supported 
by different studies, including a phase II study in which administration of the TNF-α antagonist lenercept 
was associated with exacerbation of symptoms in MS patients [156], and case reports linking etanercept 
treatment with the onset of MS [157,158]. In general, specifically blocking TNFR1 or stimulating 
TNFR2 signaling may provide a promising therapeutic possibility in MS. It should be noted, however, 
that TNFR1 might also have beneficial effects in MS. For example, it has been suggested that TNFR1 
signaling is important for the onset of EAE, but also for limiting EAE progression at a later stage [115]. 
Therefore, specific modulation of TNF-α receptor-mediated signaling at specific stages of the disease 
may be a promising approach for effective outcomes in MS. 
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Table 1. Summary of the TNF-α family members that are subjects of this review, and their roles in neurodegenerative conditions. 
 
 
Condition TNF-α family 
member 
Tissue Finding  Model Ref. 
Alzheimer’s 
disease (AD) 
TNF-α CNS TNF-α protein levels are increased in AD brain tissue. Human AD patients. [86–88] 
Plasma and serum TNF-α protein levels are increased in AD plasma and serum. Human AD patients. [83–85] 
TNFR1 and 
TNFR2 
CNS TNFR1 protein levels are increased, TNFR2 protein levels 
are decreased. 
Human AD patients. [88,93] 
Deletion of both TNFRs exacerbates AD pathology.  3xTg-AD mouse model. [96] 
Silencing or deletion of TNFR2 aggravates AD pathology. 
TNFR2 overexpression reverses these effects.  
3xTg-AD mouse model 
and APP23 mouse model. 
[97]  
In vitro, TNFR2 silencing promotes Aβ neurotoxic effects.  SH-SY5Y cell line.  [100] 
Deletion of TNFR1 diminishes AD pathology.  3xTg-AD mouse model 
and APP23 mouse model.
[91] 
sTNF-α inhibitors diminish AD pathology.  3xTg-AD mouse model. [99] 
sTNFR1 and 
sTNFR2 
CSF, serum and 
plasma 
sTNFR1 levels are increased. 
sTNFR2 levels are unchanged or decreased. 
Human control and MCI 
patients. 
[159–163] 
Higher sTNFR1 serum levels can predict conversion from MCI 
to AD. 
Human control and MCI 
patients. 
[161] 
sTNFR1 and sTNFR2 levels correlate with BACE1 activity 
and Aβ40 levels, as well as with tau CSF levels. 





TNF-α CNS and CSF TNF-α levels are increased in brain and CSF.  Human control and PD 
patients. 
[96,98] 
TNF-α levels are increased in brain. α-Synuclein overexpression 
cell line and mouse models. 
[106] 
TNFR1 CNS TNFR1 levels are increased in the substantia nigra.  Human control and PD 
patients. 
[105] 
sTNF-α inhibitors reduce cell death of dopamine neurons. Rat 6-OHDA toxicity model.  [111–114] 
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Table 1. Cont. 
Condition TNF-α family 
member 
Tissue Finding  Model Ref. 
Parkinson’s 
disease (PD) 
TNFR2 CNS Selective activation of TNFR2 protects dopaminergic neurons. Neuronal culture, 




CNS Deletion of both TNFRs protects from dopaminergic toxicity, 
while lack of either TNFRs alone is not protective.  
Mouse, MPTP toxicity 
model.  
[116] 
sTNFR1 Serum and 
plasma 




Higher serum sTNFR1 correlate with a later onset of sporadic PD. Human control and PD 
patients. 
[165] 
Elevated plasma sTNFR1 levels predict poorer executive 
functioning in PD.  





TNF-α CNS TNF-α production is increased around the lesion site.  Human brain tissue and 
animal models of stroke. 
[117–120] 
Inhibition of TNF-α reduces infarct size and neuroinflammation. Stroke mouse models.  [122–125] 
TNFR1 CNS TNFR1 knockout mice have larger infarct sizes compared to 
wild-type and TNFR2 knockout mice.  
Stroke mouse model. [134,135] 
TNFR1 is responsible for expression of neuroprotective factors 
upon ischemia.  
Stroke mouse model. [135,136] 
Absence of TNFR1 reduces retinal ischemia-reperfusion damage.  Mouse retinal ischemia-
reperfusion model.  
[16] 
TNFR1 signaling causes neuroinflammation and neurovascular 
damage in the immature brain.  
LPS-sensitized hypoxic-
ischemia mouse model.  
[138] 
TNFR2 CNS Absence of TNFR2 aggravates retinal ischemia-reperfusion damage. Mouse retinal ischemia-
reperfusion model. 
[16] 
TNFR2 silencing increases cell injury upon hypoxic conditions. SH-SY5Y cell line. [100]  
TNFR2 signaling can result in inflammatory ischemia.  Stroke mouse model. [137] 
TNFR1 and 
TNFR2 
CNS Deletion of both TNFRs aggravates neuronal damage.  Stroke mouse model.  [5] 
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Table 1. Cont. 
 
Condition TNF-α family 
member 




TNF-α CNS TNF-α levels are increased in MS lesions. Human MS brain tissue. [140,141] 
Constitutive TNF-α overexpression can cause a spontaneous 




TNF-α knockout increases demyelination and inflammation.  EAE mouse model.  [144,145] 
TNF-α knockout delays both demyelination and remyelination. Cuprizone mouse model. [146] 
General blockage of TNF-α by etanercept is linked to onset of 
MS in human case reports.  
Human case reports.  [157,158] 
General blockage of TNF-α by lenercept may exacerbate 
symptoms in human MS patients.  
Human MS patients.  [156] 
TNFR1 CNS TNFR1 knockout mice do not develop EAE or have a less severe 
disease course. 
EAE mouse model.  [18, 
152–154] 
TNFR1 signaling induces oligodendrocyte apoptosis and 
primary demyelination.  
TNF-transgenic mice.  [147] 
TNFR1 may contribute to inflammatory infiltration of the 
spinal cord. 
EAE mouse model. [148] 
Selective inhibition of TNFR1 signaling ameliorates 
EAE-induced pathology.  
EAE mouse model.  [18,149] 
sTNF-α inhibition protects against EAE symptoms.  EAE mouse model.  [150,151] 
TNFR2 CNS TNFR2 knockout mice show aggravated demyelination and 
disease symptoms.  
EAE mouse model.  [18, 
152–154] 
TNFR2 signaling mediates remyelination and oligodendrocyte 
precursor cell proliferation.  
Cuprizone mouse model. [146] 
Selective stimulation of TNFR2 protects primary 
oligodendrocytes from oxidative stress.  
Primary oligodendrocyte 
cell culture.  
[155] 
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3.5. Other Neurodegenerative Disorders 
Besides the four conditions described above, there are certainly many other disorders with 
neurodegenerative features in which a role for TNF-α has become clear. Although for this review we have 
chosen to focus on AD, PD, ischemic stroke, and MS, investigation of TNF-α and its receptors in other 
neurodegenerative conditions may also greatly contribute to the understanding of TNF-α’s effects, and 
the factors on which these effects depend. Examples of other disorders in which TNF-α has been implicated 
include traumatic brain injury (TBI) [167], epilepsy [168], and Huntington’s disease (HD) [169,170]. 
Evidence exists that TNFR1 signaling may exacerbate cognitive dysfunction in a mouse model of TBI, 
while TNFR2 signaling may attenuate it [171,172]. Also, in models of epileptic seizures, inhibition of 
TNFR1 signaling as well as activation of TNFR2 were suggested to protect against seizure-induced 
neuronal damage [168,173,174]. In in vitro and in vivo models of HD, blockage of sTNF-α by XPro-1595 
was shown to reduce different pathological features of HD [175]. Another group of diseases in which  
TNF-α signaling may play an important role is lysosomal storage disease (LSD). LSDs are rare, and 
result from mutations in lysosomal enzyme-encoding genes, causing the enzyme’s substrate to accumulate 
in the lysosomes. Depending on the enzyme that is affected, different substrates may pile up, leading to 
different LSDs. More than 30 LSDs are known, and include, for example, Fabry disease, Pompe disease, 
Gaucher disease, and Niemann-Pick type C (NP-C) disease [176]. In the majority of LSDs neurodegeneration 
occurs, with neuroinflammatory processes being implicated as important contributors [177–179]. In 
human NP-C patient brain tissue as well as in a mouse model of this disease, apoptotic neurons were 
detected. Interestingly, in affected brain regions in an NP-C mouse model, the expression of different 
components in TNF-mediated apoptotic signaling was found to be increased, including that of TNF-α 
itself, TNFR1, and caspase-8 [180]. Gaucher disease patients showed elevated serum TNF-α levels, and 
in the fetal brains of a Gaucher disease mouse model, TNF-α levels (as well as the levels of different 
other pro-inflammatory cytokines) were increased [181,182]. Also, after birth, TNF-α and TNFR1 were 
found to be upregulated in the brains of Gaucher disease mice with increasing age and disease  
severity [183]. All in all, there are many conditions with neurodegenerative components in which  
TNF-α signaling may significantly contribute to neuropathological processes, and more research 
focusing on TNF-α signaling via either TNFR1 and TNFR2 is warranted. 
4. TNFR1- and TNFR2-Mediated Signaling in Neurodegeneration 
Despite the overlap between the signaling pathways of TNFR1 and TNFR2, their effects can differ 
greatly. For example, although both receptors may cause activation of transcription factor NF-κB 
(however with different activation kinetics [59]), different genes are transcribed depending on which 
TNFR was activated. The involvement of possible TNFR1 and TNFR2 downstream signaling pathways 
in neurodegenerative disorders will be discussed based on studies using TNFR1- and/or TNFR2-specific 
knockout animals, or compounds targeting TNFRs specifically. 
4.1. TNFR1—Possible Downstream Targets in Neurodegeneration 
Neutrophil gelatinase-associated lipocalin (NGAL, also known as lipocalin 2, the murine orthologue 
of NGAL) is a recently described downstream product of TNFR1-mediated signaling [184]. NGAL plays 
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a role in the innate immune system, and is important in the defense against certain bacteria [185]. 
Mounting evidence recently provided insights into interesting functions of NGAL in the brain, 
particularly its role in neurodegenerative disorders. Robust increased NGAL protein levels were found 
in AD post-mortem human brain tissue [184], a mouse model for MS [186], and mouse model for 
cerebral ischemia [187]. Increased NGAL protein levels are detrimental to neuronal health [188] and 
sensitize neurons and other brain cell types to cell death upon exposure to Aβ and oxidative  
stress [184,189,190]. In addition, NGAL was shown to further promote pro-inflammatory reactions, and 
to stimulate classical inflammatory activation of microglia and astrocytes [191,192]. NGAL plays an 
interesting role in TNF-α-mediated signaling pathways. Our research group showed that NGAL is solely 
increased and secreted upon TNFR1 stimulation in murine primary neurons, astrocytes, and microglia 
cells. Increased NGAL in turn silences the TNFR2-mediated PI3K-PKB/Akt pathway in neurons, 
possibly by increasing PTEN levels [184]. Thus, NGAL may play an important role in shifting TNF-α 
signaling towards TNFR1-mediated pathways observed in different neurodegenerative conditions, as 
previously described in this review. 
Different studies demonstrated that TNFR1 can induce matrix metalloproteinase 9 (MMP-9) 
expression [193–195]. In the A549 cell line (a human lung adenocarcinoma epithelial cell line), TNF-α 
can induce MMP-9 expression via a TNFR1/TRAF2/PKC alpha-dependent pathway [193]. MMP-9 has 
been associated with different physiological and pathophysiological processes. For example, MMP-9 
was shown to be able to interact with Aβ, and can play a role in the disruption of the blood-brain  
barrier [196–199]. This latter effect seems to be associated with MMP-9’s actions in the degradation of 
the extracellular matrix. Of note, it was shown that MMP-9 can form a complex with NGAL, and that 
NGAL may elongate the activity of MMP-9 [200]. 
TNFR1 could engage in processes concerning the clustering of the α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA) receptor (AMPAR). Deletion of TNFR1 was found to suppress 
excitatory synaptic transmission via the localization of AMPA receptors to the synapses of cortical 
neurons [201]. It was therefore suggested that TNFR1 might be involved in AMPAR-mediated 
excitotoxicity. Furthermore, it was shown that TNFR1 signaling induces excitotoxicity by promoting 
glutamate release in mouse primary microglia and astrocyte cell cultures [202–204]. More specific to 
AD, TNFR1 was found to be involved in the processing of the amyloid precursor protein (APP) and Aβ 
plaque formation by increasing BACE1 promotor activity [91]. 
4.2. TNFR2—Possible Downstream Targets in Neurodegeneration 
Examples of TNFR2-specific signaling in neurodegeneration have also been described [16,59]. Dolga 
et al. identified certain small conductance calcium-activated potassium K(Ca)2 channels as downstream 
products of TNFR2 signaling [129,205]. These channels contribute to neuroprotection against neuronal 
overstimulation by lowering the neuronal excitability. It is specifically the expression of K(Ca)2.2 that 
was shown to be downstream of TNF-α/TNFR2 signaling via NF-κB activation. As such, it was 
suggested that in primary cortical neurons, TNF-α induces K(Ca)2.2 channel activation, resulting in 
neurons that are more resistant to excitotoxic cell death by preventing intracellular calcium levels to 
become pathologically high [129,205]. In the past years it has been shown that K(Ca)2 channels may 
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also be involved in mechanisms contributing to the plasticity of the hippocampal CA1 neurons and in 
learning and memory [206,207]. 
Fischer et al. (2014) showed that TNFR2-mediated activation of the PI3K-PKB/Akt pathway in 
primary astrocytes induces the expression of different neuroprotective genes, including the gene that 
encodes leukemia inhibitory factor (LIF) [208]. LIF is a neurotrophic cytokine, which, in the brain, is 
mainly produced by astrocytes. Elevated levels of LIF were shown to promote the maturation of 
oligodendrocytes [208], and LIF was found to protect primary neurons against excitotoxicity [209]. 
Moreover, in the EAE mouse model LIF was demonstrated to protect axons in the brain from acute 
inflammatory damage [210]. 
Other downstream products of TNFR2 signaling include CXCL12, which has also been implicated 
in the proliferation and differentiation of oligodendrocyte progenitor cells [211]. Moreover, its levels 
were found downregulated in the Tg2576 AD mouse model, and reduced CXCL12 levels were shown 
to cause impairments in learning and memory [212]. Lastly, TNFR2 signaling in microglia has been 
related with the induction of anti-inflammatory pathways, for example the upregulation of IL-10 [213]. 
All examples discussed in this chapter support the idea that TNFR1 may specifically induce factors 
that contribute to neurodegenerative processes, while TNFR2 specifically mediates factors involved in 
neuroprotective mechanisms (Figure 3). However, in agreement with the rest of this review, things are 
certainly far more complex. Therefore, different unknowns and contradictory findings underlining and 
adding to the complexity of TNF signaling will be addressed in the following chapter. 
 
Figure 3. Examples of specific downstream targets of TNFR1 and TNFR2 that may be 
involved in neurodegenerative disorders. Dotted lines indicate existing potential therapeutic 
approaches. Other general TNF-α blockers, not depicted in this figure, include adalimumab, 
certolizumab pegol, and golimumab. Other new TNFR1-specific antagonists include 
DMS5540 and TROS (also see review by Fischer et al., 2015 [214]). 
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5. Complex matters: TNFR1 Signaling Is Primarily Damaging and TNFR2 Beneficial? 
Although in this paper we generally highlighted an important neuroprotective role for TNFR2 and a 
neurodegenerative role for TNFR1 in different neurodegenerative disorders, findings that contradict this 
idea cannot be ignored. As described in the previous paragraphs, for several neurodegenerative disorders 
conflicting results have been found concerning beneficial/detrimental effects of TNFR1 and TNFR2 
signaling. These contradictory findings emphasize the complexity of TNFR1/TNFR2 signaling, and 
confirm that our understanding of TNF signaling is still a work in progress. 
The outcome of TNF-α signaling will likely depend on many variables: the availability of both 
receptors, the available levels of sTNF-α and mTNF-α ligands, the availability of the components in 
their respective signaling cascades, and the level of crosstalk between the two pathways, all of which 
likely depend on the cell type, tissue, and the condition. Indeed, different studies have suggested that 
TNF-α signaling may be strongly brain region-specific, which may in part depend on, e.g., the relative 
density and activity of microglia in specific regions [213,215,216]. Also, the timing of TNF-α signaling 
in different stages of neurodegeneration could affect the outcomes of TNF-α. For example, TNF-α mediates 
a neuroprotective effect when hippocampal organotypic slice cultures are treated with TNF-α before an 
ischemic insult (which may simulate ischemic preconditioning), but has neurotoxic effects when 
administered after the same ischemic insult [217]. Furthermore, TNFR2-mediated pathways have received 
less attention compared to TNFR1, and undefined signaling mechanisms possibly remain to be discovered. 
These and other factors greatly increase the complexity of TNF signaling, and a few will be further 
discussed below. 
5.1. Selective Harmful Downstream Targets of TNFR1 and Beneficial Downstream Targets of TNFR2? 
Although Chapter 4 described examples supporting the presence of potent detrimental downstream 
signaling pathways mediated specifically via TNFR1, while TNFR2 signaling may mostly activate genes 
with potential neuroprotective functions, matters are often not that clear-cut. For instance, it should be 
noted that there are certain examples available of neuroprotective pathways induced via TNFR1, and 
damaging outcomes of TNFR2 signaling. For example, a known downstream target of TNFR1 is nerve 
growth factor (NGF), which is important for the survival and growth of neurons [218], while TNFR2 
may also promote expression of potentially detrimental factors, such as intercellular adhesion molecule-1 
(ICAM-1), which has been associated with neuroinflammation and neurodegeneration [219,220]. 
Moreover, the specificity of certain downstream products to either TNFR1 or TNFR2 is sometimes 
unclear. For example, some studies have implied NGF to be solely induced via TNFR1 in fibroblasts, 
while it appeared in astrocytes that signaling via both receptors can cause NGF production [218,221]. 
Such contradictory findings may, among others, depend on variables like the cell type studied, the 
proximate cellular conditions, TNFR1-TNFR2 signaling kinetics, and crosstalk between the receptors. 
In addition, although the above-described processes were found to be specifically induced via either 
TNFR1 or TNFR2, there may very well be multiple other (TNF-α-independent) pathways that may 
influence TNF-α-mediated pathways and their outcomes. For example, it may be good to keep in mind 
that lymphotoxin α (TNF-β) can also bind both TNFR1 and TNFR2. Comparable to TNF-α, lymphotoxin 
α also has been implicated in different processes in the brain, and in the pathogenesis of conditions 
including MS [222,223]. 
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5.2. Soluble TNF Receptors 
Adding to the complexity of TNF-α signaling, besides membrane TNF receptors (mTNFRs), soluble 
TNF receptors (sTNFRs) also exist, which influence TNF-α signaling mechanisms as well. sTNFRs 
(sTNFR1 and sTNFR2) can be formed via a process known as ectodomain shedding, in which the 
extracellular domains of membrane TNFRs are cleaved off by TACE (which thus shows to have more 
targets besides mTNF-α) and released into the extracellular space. Notably, in addition to ectodomain 
shedding, it has been described that TNFR1 can also end up in the extracellular space via exocytosis. 
This generates exosome-like vesicles with full-length TNFR1 incorporated in the vesicle membrane [224]. 
The exact functions and mechanisms of actions of sTNFRs (as well as the full-length TNFR1 within 
vesicles), however, remain elusive. Shedding of mTNFRs is thought to regulate the actions of TNF-α, 
firstly by diminishing the number of mTNFRs on the cell membrane, and secondly by binding of 
sTNFRs to TNF-α, thereby preventing TNF-α from binding to and activating mTNFRs. Alternatively, it 
was suggested that sTNFRs bind to sTNF-α and subsequently stabilize and preserve the bio-active 
trimeric forms of TNF-α [225]. As such, sTNFRs levels might reflect the activity of TNF-α. 
Interestingly, intravenous injection of TNF-α in human volunteers suggested that TNF-α is a potent 
mediator of increased sTNFR1 and sTNFR2 release [226]. 
Different studies indicate that the levels of sTNFR1 as well as TACE activity are increased in plasma, 
serum, and CSF from AD patients [159–163]. Moreover, Diniz et al. (2010) showed that higher serum 
sTNFR1 levels can predict conversion from mild cognitive impairment (MCI) to AD [161]. Plasma and 
CSF sTNFR2 levels were found to be increased in AD by some groups [159,160], while other studies 
showed no differences in sTNFR2 levels [161,162]. Similar to AD, increased serum sTNFR1 levels were 
found in patients with PD [102,104,165]. Also, a single nucleotide polymorphism in the gene encoding 
TNFR1, resulting in production of a soluble form of TNFR1 that is able to antagonize TNF-α, was found 
to be associated with MS [227]. Although in these cases the exact meaning of these increased serum 
sTNFR1 levels is not clear, it was found that higher serum sTNFR1 levels are associated with a later 
onset of sporadic PD [165]. In addition to the potential functions and effects of sTNFRs described above, 
sTNFRs may also influence TNF-α signaling via reverse signaling through mTNF-α. 
Besides being a ligand for TNFR1 and TNFR2, mTNF-α can also act as a receptor itself. Thus, in 
addition to inducing a signaling cascade in TNFR1/TNFR2-expressing cells, mTNF-α can also elicit a 
signal transduction pathway back into the cell on which it is expressed [228]. This process is called 
reverse signaling, and can occur when mTNF-α is bound by a (s)TNFR or agonistic antibody [228,229]. 
sTNFRs may have significant effects on cells by inducing reverse signaling. For example, it was reported 
that sTNFR1 can induce apoptosis of monocytes through reverse signaling via mTNF-α. It appeared that 
this sTNFR1-induced apoptosis is independent of death receptor pathways, but is mediated via autocrine 
transforming growth factor beta (TGF-β) through p38 MAPK [230]. In addition, it was recently shown 
in cultured superior cervical ganglion (SCG) neurons that sTNFR1 promotes sympathetic axon growth 
and branching through reverse signaling via mTNF-α, and relies on downstream activation of ERK [231]. 
In addition to endogenous (s)TNFRs, different TNF-α inhibitors (such as etanercept and infliximab) 
can induce reverse signaling through mTNF-α as well. As suggested in recent studies, effects of such 
compounds may significantly depend on reverse signaling, besides the effects arising from the 
prevention of mTNF-α and sTNF-α to bind their TNFRs [232,233]. 
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Taken together, soluble TNFRs may play a substantial role in how TNF-α interacts and functions 
with its receptors, possibly especially in a systemic pro-inflammatory environment. This is an interesting 
and noteworthy research field that can provide important insights in TNF-α functioning. In theory, a 
potential therapeutic strategy to reduce excessive TNFR1 signaling may be to stimulate TNFR1 
ectodomain shedding. Interestingly, some mediators (with aminopeptidase regulator of TNFR1 shedding 
(ARTS-1) appearing as a key regulator) have been identified that are essential for TNFR1 shedding but 
do not affect TNFR2 shedding [234,235]. While ARTS-1 also participates in shedding of other receptors 
besides TNFR1 (including IL-6R and IL-1R2 [236]), downstream effectors of ARTS-1 may prove to be 
TNFR1-specific, and could provide a therapeutic target. 
5.3. Interaction between TNFR2 and Interleukin-17 Receptor D 
Moreover, the signaling of membrane TNFRs may also hold more complexity than has become clear 
so far. For example, it was very recently demonstrated that TNFR2 (but not TNFR1) can form a 
heteromer with interleukin-17 receptor D (IL-17RD, also known as Sef), leading to activation of NF-κB 
signaling via TRAF2 recruitment [237]. Depletion of IL-17RD was found to impair TNFR2-mediated 
activation of NF-κB. The complex between IL-17RD and TNFR2 was shown to be formed in HK-2 and 
786-O cell lines (a human proximal tubular cell line derived from normal kidney and a human renal cell 
adenocarcinoma cell line, respectively), and also in rat and mouse renal tissue. This indicates that the 
interaction between TNFR2 and IL-17RD may arise under physiological conditions [237]. 
All these complex issues and unknowns emphasize that gaps remain in the basic understanding of 
TNF-α signaling, which may challenge the identification of suitable TNF-targeting therapeutics for 
different neurodegenerative disorders. 
6. Targeting TNF-α Signaling: An Opportunity for Treatment of Neurodegenerative Disorders? 
As concluded in this review, targeting TNF-α signaling towards its neuroprotective functioning could 
provide potent therapeutic strategies for patients with neurodegenerative disorders. It seems that therapeutics 
could aim at a certain step of TNF-α-mediated signaling pathways via inhibiting detrimental pathways. 
6.1. Targeting TNF-α as Treatment for Neurodegenerative Disorders 
Because TNF-α is a key inductor in some inflammatory diseases such as rheumatoid arthritis (RA), 
psoriatic arthritis (PsA), Crohn’s disease (CD), as well as some neurodegenerative disorders, directly 
inhibiting this cytokine could prevent or treat those conditions. A number of researchers have 
demonstrated that directly blocking the actions of TNF-α via anti-TNF-α antibodies and its antagonists 
indeed can ameliorate inflammatory and neurodegenerative disorders [238–240]. Additionally, 
inhibition of sTNF-α was shown to promote axon preservation and remyelination in the EAE mouse 
model [151]. Due to its therapeutic capability, treatments aimed at inhibiting the functions of TNF-α have 
been shown as effective treatment strategies for RA, PsA, and CD in experimental trials and are currently 
being used worldwide in the clinical setting [19,241–243]. So far, pharmaceutical anti-TNF-α agents 
that include thalidomide analogues which inhibit the production of TNF-α have been applied for the 
treatment of RA [244–246]. Moreover, other pharmaceutical agents including etanercept, adalimumab, 
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and infliximab, which can bind both sTNF-α and mTNF-α, thereby inhibiting their signaling, have been 
successfully applied for treatment for RA and PsA [247]. Studies into the effects of such pharmaceuticals 
in neurodegenerative disorders like AD, PD, and MS, however, remain limited. 
Drugs targeting TNF-α for systemic inflammatory diseases still have adverse effects in a minority of 
patients [248]. For instance, anti-TNF-α therapy for RA induces the risk of serious infections of the skin, 
soft tissues, and joints [249]. Anti-TNF-α agents increase risk rates of malignancies in patients with 
inflammatory bowel disease [250]. It has been mentioned that two patients with rheumatoid arthritis 
treated with an anti-TNF-α strategy developed neurological symptoms, including demyelination  
lesions [251]. Furthermore, it was shown that newborns presented severe neutropenia after their mothers 
were treated with infliximab for ulcerative colitis during pregnancy [252]. 
To reduce or diminish the drawbacks of anti-TNF-α agents in inflammatory diseases and 
neurodegenerative disorders, other therapeutic strategies should be investigated. Considering the various 
outcomes of TNF-α, targeting a specific point in its signaling pathways could be more effective and 
decrease the negative effects associated with anti-TNF-α agents. 
6.2. Targeting TNFRs as Treatment for Neurodegenerative Disorders 
In essence, TNFR1 has often been demonstrated to deteriorate or aggravate neurodegeneration, 
whereas TNFR2 mediates neuroprotection. Therapeutics that specifically modulate the signaling 
mechanisms of TNF-α, i.e., blocking TNFR1 actions and/or increasing the TNFR2 signaling pathway, 
could greatly reduce the side effects of current anti-TNF-α approaches. Sedger’s group [253] discovered 
that a leporipoxvirus TNF receptor homolog by its N-terminal preligand assembly domain (PLAD)-
homologous domain interacts with the intracellular domain of TNFR1 and showed that this interaction 
results in a heterocomplex that inhibits TNFR1 downstream signaling and significantly prevents 
TNFR1-induced apoptosis of lymphocytes. Selectively blocking the bioactivity of sTNF-α, thus preventing 
TNFR1-mediated signaling, attenuated the pathological symptoms in EAE mice [150,151]. Furthermore, 
a soluble TNFR1-selective antagonistic mutant TNF (named R1antTNF) ameliorated the symptoms in  
EAE mice [149,254]. Currently, an antagonistic TNFR1-specific antibody has been produced and 
demonstrated to treat MS clinical symptoms more efficiently in EAE mouse model [18]. Another human 
TNFR1-specific antagonistic antibody that may prove to have therapeutic effects is ATROSAB [255,256]. 
As TNFR1 is mainly activated by sTNF-α, selectively inhibiting sTNF-α may prevent TNFR1-mediated 
apoptosis and could be a therapeutic strategy in neurodegenerative disorders. In this regard, a blocker of 
sTNF-α, XPro-1595, significantly improved the cognitive deficits induced by spinal cord injury in mice 
compared to the drug etanercept [257]. Furthermore, Tansey et al. [258] discovered that XPro-1595 
significantly reduced activation of microglia and astrocytes, and prevented loss of dopamine neurons in 
a rat model of PD. Shedding of TNFR1 mediated by iNOS-cGMP-TACE signaling has been suggested 
to significantly ameliorate the inflammation associated with sepsis [259]. Increased sTNFR1 levels 
resulting from this TNFR1 shedding could compete to bind to sTNF-α and impair TNFR1-mediated 
downstream signaling pathways and potentially reduce its apoptotic signaling pathways. 
TNFR2-mediated signaling could be used as a therapeutic approach for neurodegenerative disorders. 
Lovastatin, which is widely used to reduce cholesterol levels in patients, has been confirmed to 
selectively increase TNFR2 expression [260]. Thereafter, it was demonstrated that lovastatin protected 
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primary cortical neurons against glutamate-induced excitotoxicity [261]. Moreover, in vivo evidence showed 
that lovastatin attenuated NMDA-induced nucleus basalis magnocelullaris (NBM) lesions and prevented 
cognitive deficits in mice [262]. This further supports the idea that TNFR2 activation could be a 
therapeutic approach for neurodegenerative disorders. Notably, Pfizenmaier’s group [110] constructed 
a soluble human TNFR2-selective agonist (TNC-scTNFR2) and demonstrated that it successfully rescues 
human neurons from oxidative stress-induced cell death. TNC-scTNFR2 is synthesized by genetic fusion of 
the trimerization domain of tenascin C to a TNFR2-selective single-chain TNF molecule, which specifically 
activates TNFR2 to promote the PI3K-PKB/Akt-NF-κB signaling pathway and promotes neuroprotection. 
Selective targeting of TNFRs as a therapeutic strategy seems a promising avenue for the treatment of 
CNS conditions and some inflammatory diseases associated with TNF-α. Of note, it should be 
established whether simultaneous targeting of both receptors is necessary to achieve maximum 
therapeutic efficacy, as compared to inhibition/stimulation of either TNFR1 or TNFR2. Moreover, the 
ability of therapeutic compounds to cross the blood-brain barrier (BBB) is an obstacle that needs urgent 
attention. TNF-α blockers like etanercept and infliximab are too large to penetrate the BBB and, of certain 
new compounds, it is yet to be examined whether they can pass the BBB. In the EAE mouse model, 
subcutaneous or intraperitoneal injections with XPro-1595 and R1antTNF were effective in reducing 
pathology [149–151]. However, seeing the involvement of the peripheral immune system in MS and EAE, 
it may be that targeting peripheral TNF-α is sufficient to reach therapeutic effects. Moreover, since the BBB 
is compromised in the EAE model, a possibility exists that these compounds may have entered the brain 
through an already leaky BBB. Nevertheless, a recent study on XPro-1595 in the 6-OHDA model for PD (in 
which the BBB is presumably not damaged enough to let XPro-1595 pass non-selectively) revealed that this 
compound could indeed reach the brain in therapeutically relevant concentrations (evidenced by inhibited 
glial activation and reduced dopamine neuron loss), after subcutaneous administration [258]. Moreover, it 
may be that certain compounds, in certain conditions, do not necessarily have to pass the BBB to reach 
therapeutic effects. For example, in rat MCAO models for cerebral ischemia beneficial effects were reported 
upon intraperitoneal injection of etanercept [124,125]. However, it may be that etanercept could enter the 
brain via disruptions in the BBB, induced by the MCAO [124]. Other important issues that will need to 
be addressed include the timing of treatment, and the potential side-effects that may arise from targeting  
TNF-α, TNFR1, and/or TNFR2. In case of ischemic stroke, start the treatment within a few hours upon 
an insult may be crucial to limit damage as much as possible. As described in Chapter 3.3, the timing of 
specific TNF treatments may be particularly delicate in acute conditions where TNFR expression levels 
may be rather dynamic in the first hours/days, for example after the stroke. Apoptotic signaling may be 
beneficial immediately upon an insult in order to clear damaged cells and protect surrounding cells. As 
such, administering, e.g., TNFR1 antagonists, may have to be very carefully timed, neither too early nor 
too late. However, for chronic conditions such as AD, PD, and MS, it can be hypothesized that beginning 
treatment in early stages may in the end prove to be most effective, but starting treatment in later stages 
may well slow down the neurodegenerative process. Furthermore, potential side-effects of TNF-
targeting compounds have to be assessed. For example, the possibility that selective inhibition of TNFR1 
or stimulation of TNFR2 signaling could negatively affect production or action of neurotrophic factors 
(such as NGF and BDNF) should be explored in future studies. 
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7. Conclusions 
As discussed in this review, TNF-α is involved in many neurodegenerative disorders by exerting both 
neuroprotective and neurodegenerative functions. A balance between these opposite effects seems to 
depend on its actions via TNFR1 and TNFR2. A thorough understanding of TNF-α signaling pathways 
can contribute to the development of potential therapeutic strategies. Focusing on multiple molecular 
interactions, which can control signaling outcomes in TNF-α signaling pathways, could be critical to 
develop preferable therapeutic strategies in the future. 
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